309
Apeiron Biologics, an Austrian biotech company, is being acquired by US-based Ligand Pharmaceuticals for US$100m. Shareholders are also entitled to additional consideration based on future commercial and regulatory events and to up to US$28m if Qarziba royalties exceed certain predetermined thresholds by either 2030 or 2034 respectively.
Concurrently, Ligand has also committed to investing up to US$4m in invIOs Holding, an Apeiron spin-off. The proceeds will help invIOs to finance the R&D of three innovative early-stage…